IRVINE, Calif. -- (Business Wire)

Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by TransEnterix, Inc. (“TransEnterix” or the “Company”) (NYSE: TRXC). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.

If you purchased shares of TransEnterix during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the Company’s April 20, 2016, press release stating that the FDA informed the Company that "SurgiBot™ System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission."

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160526006556/en/

Contacts:

KHANG & KHANG LLP
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

Source: Khang & Khang LLP